Teriflunomide API

Name	Teriflunomide
Chinese name	特立氟胺
Cas Number	108605-62-5
Source	India
Qualifications	USDMF/-/-/-/-

Teriflunomide original drug is a hydroorotate dehydrogenase inhibitor developed by Sanofi. It has immunomodulatory effects and can inhibit experimental allergic encephalomyelitis. It was approved for use in the United States in September 2012 For the treatment of relapsed MS in adults. Clinical studies have shown that: teriflunomide is safe and well tolerated, and the incidence of adverse reactions is low. It can not only significantly reduce the annual recurrence rate of MS, but also reduce the risk of disability progression. In addition, teriflunomide is easy to use and only needs to be taken orally once a day. At present, the drug has been approved in more than 70 countries and regions around the world. The "2018 China Multiple Sclerosis Diagnosis and Treatment Expert Consensus" recommends teriflunomide as the first-line treatment for remission, for the control of disease progression, with good clinical and market prospects. Teriflunomide is the first oral multiple sclerosis treatment drug marketed in my country. It has many advantages and should be a hot spot for imitation.

Hot Tags: teriflunomide api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Lapatinib Ditosylate API, Lercanidipine Hydrochloride API, Dimethyl Fumarate API, Ranolazine API, Fulvestrant API, Vinpocetine API

• Previous: Pazopanib Hydrochloride/Pazopanib API
• Next: Troxagliptin Succinate API